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Abstract
Background: In Finland, buprenorphine (Subutex) is the most abused opioid. In order to curb this
problem, many treatment centres transferred ("forced transfer") their buprenorphine patients to
the buprenorphine plus naloxone (Suboxone) combination product in late 2003.
Methods: Data from a retrospective study involving five different treatment centers, examining
the effects of switching patients to Suboxone, were gathered from 64 opioid-dependent patients
who had undergone the medication transfer.
Results: Most patients (90.6%) switched to Suboxone at the same dose of buprenorphine that they
had been receiving as Subutex (average 22 mg). The majority of these patients (71.9%) were
maintained at the same dose of Suboxone throughout the 4-week study period. During the first 4
weeks, 50% of the patients reported adverse events and at the four month time point, 26.6%
reported adverse events. However, due to adverse events one patient only discontinued treatment
with Suboxone during the 4-week study period, and five during the four month follow-up period.
Of the 26 patients in the follow-up period, Suboxone was misused intravenously once each by 4
patients and twice by 1 patient. These 5 patients all reported that injecting Suboxone was like
injecting "nothing" with any euphoria, or that it was a bad experience.
Conclusion: We conclude that when patients are transferred from high doses (> 22 mg) of
buprenorphine to the combination product, dose adjustments may be necessary especially in the
later phase of the treatment. We recommend that a transfer from Subutex to Suboxone should be
carefully discussed and planned in advance with the patients and after the transfer adverse events
should be regularly monitored. With regard of buprenorphine IV abuse, the combination product
seems to have a less abuse potential than buprenorphine alone.
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Background
Buprenorphine is a mu-opioid receptor partial agonist
and kappa-opioid receptor antagonist. The high dose sub-
lingual tablet formulation (Subutex) has proven an effec-
tive treatment for opioid dependence [1] and is in use in
over 40 countries worldwide. The buprenorphine plus
naloxone (Suboxone) combination tablet was developed
with the objective of having the same sublingual effective-
ness and safety profile as buprenorphine alone (Subutex)
but with a lower intravenous (IV) misuse potential [2].
Naloxone, when taken sublingually, is poorly absorbed
and should have little or no pharmacological effects [3].
When Suboxone is injected intravenously, naloxone is
intended to precipitate withdrawal effects in opioid-
dependent users, to attenuate feelings of "drug liking",
and to provide a generally unpleasant experience [3]. Sub-
oxone is presently approved for use in the United States,
Canada, Australia, New Zealand, Malaysia, and recently in
the European Union.
In Finland, the most misused IV opioid during the last few
years has been buprenorphine [4] mainly originating
from other countries, notably France. As a consequence of
abuse, access to and monitoring of the treatment has been
very strictly controlled, thus necessitating significant
resources. At the initiation of this study approximately
200 patients were receiving treatment with Subutex in Fin-
land. When Suboxone became available under special
license in Finland towards the end of 2003, several treat-
ment centers switched their patients rapidly from Subutex
to Suboxone as a strategy to curb misuse of buprenor-
phine.
Preliminary data are available from an open label study
involving the switching of patients from low-dose Subu-
tex to Suboxone in Australia indicating a need for a dose
increase [5]. In contrast, the relative bioavailability of dif-
ferent buprenorphine formulations under chronic dosing
conditions has also been studied, and it is possible that
the buprenorphine in Suboxone has a slightly higher sub-
lingual bioavailability than the buprenorphine in Subutex
[6]. However, detailed effects of switching therapy from
Subutex to Suboxone have not been fully investigated.
The study objectives were threefold: i) to examine the
potential effect of a switch on the total dose of buprenor-
phine, ii) to follow whether the switch to Suboxone deters
IV misuse, and iii) to follow whether switching from Sub-
utex to Suboxone results in withdrawal symptoms or
other significant adverse reactions.
Methods
The study was retrospective, involving data collection
from 64 opioid-dependent patients who had undergone a
switch from Subutex to Suboxone. The inclusion criteria
were as follows: opioid dependency (ICD-10); patient sta-
bilized on buprenorphine treatment for at least a month;
a buprenorphine dose of at least 12 mg/day, the average
buprenorphine daily dose in Finland in 2004 was 21 mg,
(however, due to Finnish clinical practice for pregnant or
lactating women the maintaining dose is generally lower,
≤ 12 mg); patient switched or attempted to switch from
Subutex to Suboxone, and older than 18 years of age. Data
were collected from five treatment sites in Finland using
structured data collection forms. The five treatment cent-
ers were randomly chosen from 20 treatment centers that
were using Subutex and had more than 10 patients in
buprenorphine treatment. All buprenorphine patients,
except four patients with low doses of buprenorphine
(pregnant women), in these centers were included in the
study. Data were collected for three days during the week
of the medication switch and at 1, 2, 3, and 4 weeks fol-
lowing the transfer. The data collection was repeated four
months post transfer (follow-up period). The data gath-
ered from patient records prior to the switch (Subutex
dose, drug misuse and frequency of clinic visits) is consid-
ered as baseline data.
Ethical Conduct of Study
The study was coordinated by the Department of Mental
Health and Alcohol Research of the National Public
Health Institute in Finland whose Ethical Committee
approved the study protocol. Patient data were collected
by the treating physician in each treatment site. Data pro-
tection was ensured throughout in accordance with the
regulations of the National Public Health Institute. The
National Public Health Institute funded the study.
Treatment Records
The treating physicians at these selected clinics collected
data about eligible patients who had undergone a "forced
transfer" from Subutex to Suboxone. Data were collected
from patient archives of the respective study sites and
stored with codes to protect the personal details of the
study patients. Physicians recorded the Subutex dose at
the day of the transfer, and the Suboxone doses used dur-
ing the four weeks following the switch. Data four months
after the study period were also collected.
Drug misuse measures were recorded as follows: (1) Drug
misuse history at the time of entering the clinic; (2) any
relevant medical history; (3) signs of buprenorphine mis-
use before the switch from Subutex to Suboxone and at
weeks 1–4 following the switch (as evidenced by the pres-
ence of fresh needle marks or patients volunteering the
information); (4) signs of misuse of other opioids (urine
tests and patient reports); and (5) current misuse of any
non-opioid drugs (urine tests and patient reports). Length
of non-opioid drug use was also recorded.Substance Abuse Treatment, Prevention, and Policy 2008, 3:16 http://www.substanceabusepolicy.com/content/3/1/16
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Adverse events considered being associated with the
switch from Subutex to Suboxone on the day of the
switch, days 2 and 3, and weeks 1 to 4 following the
switch were recorded. Adverse events four months after
the study period were also collected. The MedDRA coding
was followed.
Overall patient complacence (patient satisfaction with the
switch to Suboxone: yes, no, why not) and compliance,
with reasons for non-compliance (where available), were
recorded on each of the weekly visits to the clinic before
and after the switch. The Finish maintenances treatment
legislation (on the time of this study) states that only
good patient compliance allows take-home medication,
and at the most for 8 days. Thus, the frequency of weekly
visits gives an indirect implication of compliance; the less
visits the better compliance.
Study sites
The 5 treatment centers were located in different parts of
Finland. Two of the centers are located in Helsinki (HDL,
HUS), one in the district of Southern Uusimaa (Espoon A-
klinikka), one in central Finland (Tampere), and one in
northern Finland (Raahe). All study doctors were either
psychiatrists or general practitioners with long experience
in maintenance treatment, and had subspecialty in addic-
tion medicine.
Primary outcomes
Primary outcomes were the dose of buprenorphine before
and after switch to Suboxone, and physical signs or
patient reports of intravenous misuse of buprenorphine.
Secondary outcomes
Physical signs of heroin and other opioid abuse/misuse or
evident from urine tests, patient's satisfaction/dissatisfac-
tion with Suboxone, and frequency of patient's visits to




The records from a total of 64 patients were examined for
this study. The mean age and other background demo-
graphics are shown in Table 1. By the end of the 4-week
study period, one patient discontinued the maintenance
treatment program and three patients were transferred
back to Subutex. Out of these three patients, one was
transferred back to Subutex due to adverse events and the
other 2 patient for a lack of compliance on Suboxone. 60
patients (93.8%) continued treatment with Suboxone
into the follow-up period.
During the four months follow-up period, the treatment
was discontinued with seven (11.7%) patients, five
(8.3%) were moved to other treatment sites (no treatment
records available), nine (15%) patients were switched
back to Subutex, 13 (21.7%) patients were transferred to
methadone, and 26 (43.3%) continued with Suboxone.
The main reasons for change of treatment or discontinua-
tion were IV misuse of buprenorphine (10 patients), mis-
use of other drugs (8 patients), adverse events (6 patients)
and dissatisfaction with Suboxone (5 patients).
Buprenorphine dose during the transfer and study periods
Weeks 1–4
Fifty-eight patients (90.6%) switched to Suboxone at the
same dose of buprenorphine that they had been receiving
as Subutex. One patient was transferred with a higher Sub-
oxone dose (2 mg), two with lower doses (2–4 mg) and
three patients were "titrated" with daily increases of Sub-
oxone (patient anxiety over the transfer) up to the previ-
ous Subutex dose (Table 2).
Out of the 60 patients finishing the 4-week study period,
53 patients (82.8%) were treated with Suboxone only
throughout the study period, and 46 of these (71.9%)
were maintained at the same dose of Suboxone (Table 3).
During the 4 week period, 4 patients (6.3%) had dose
reductions and 1 patient (1.6%) had a dose increase with
Suboxone. Two patients (3.1%) had temporary dose
changes during the 4-week study period and seven
patients had titrated dosing (2–3 day interval in increase).
Four month follow-up
Out of the 26 patients continuing treatment with Subox-
one, 10 patients (38.5%) were treated with the same dose
of Suboxone, 15 patients (57.7%) had dose reductions,
and 1 patient (3,8%) had a dose increase
Drug abuse
At baseline, 9 patients (14.1%) showed physical evidence
of IV drug misuse and 7 reported it being buprenorphine
and two heroin. Forty-seven patients (73.4%) indicated
that they were not abusing buprenorphine or heroin and
showed no signs of IV misuse. Information on IV misuse
of buprenorphine was not recorded for 8 patients
(12.5%). Twenty patients (31.3%) reported abuse of
other drugs also (cannabis, amphetamine, benzodi-
azepines).
Table 1: Background characteristics of the patients (n = 64)
Gender, male (n) 52
Age, mean (± SD) 29.9 ± 7
Duration of heroin use (month) mean ± SDa 72.2 ± 94.2
Buprenorphine treatment (days) mean ± SD 63.3 ± 363
Subutex mean daily treatment dose (mg) ± SD 22.9 ± 5.4
a59 patients reported history of heroin useSubstance Abuse Treatment, Prevention, and Policy 2008, 3:16 http://www.substanceabusepolicy.com/content/3/1/16
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At weeks one, two and three, seven, three and six patients,
respectively, showed signs of IV abuse of buprenorphine
(Subutex or Suboxone). Three patients who had records of
IV-misuse at baseline did not continue misusing during
the 4-week follow up period, and three new patients with
IV-misuse were observed during this period. Over the 4-
week study period, there was no evidence of misuse of
other opioids.
During the follow-up period the total number of incidents
of IV opiate abuse remained at the same, 10 patients were
recorded as showing signs of intravenous buprenorphine
(Subutex or Suboxone) misuse and 1 patient informed the
investigator that he had used heroin. One patient tested
positive for codeine, which was permitted for a known
complaint. Of the buprenorphine IV abuse, Suboxone was
misused intravenously once each by 4 patients and twice
by 1 patient. These 5 patients all reported that injecting
Suboxone was like injecting "nothing" with any euphoria
or that it was a bad experience. Four of them reported also
that while they tried to inject Suboxone, they would not
repeat the experience.
Complacence and Compliance
Overall, more than 60% of patients were compliant with
Suboxone treatment throughout the 4-week study period.
The highest rate of compliance occurred at Centre Raahe
where all patients used Suboxone treatment throughout
the 4-week study period. During the 4-week observation
period, approximately half the patients were satisfied with
Suboxone treatment. At centre HDL, patient satisfaction
was 28.6% at week 4 while it ranged from 50.0% to 66.7%
at the other 4 centers. Clinic visits across the centers varied
from once per week to five visits per week. The switch
from Subutex to Suboxone did not change the frequency
of visits, and frequency did not change over the 4-week
study period. The patient satisfaction did not correlate to
the number of visits/clinic or the dose of Suboxone used.
Twenty-four patients (37.5%) were satisfied with the
switch from Subutex to Suboxone every time the question
was asked during the 4-week study period, and 26 patients
(40.6%) were dissatisfied every time they were asked. The
14 other patients (21.9%) were satisfied at some point
during the 4-week study period, and 9 of these patients
were satisfied at the end of the 4-week study period.
Twenty-six of the 27 patients (96.3%) who were still being
treated with Suboxone at the end of the 4-month follow-
up were satisfied.
Adverse events
During the four week study period, 32 of the 64 patients
(50.0%) reported adverse events (Table 4). Gastrointesti-
nal adverse events were the most commonly reported
adverse events. Nausea and gastrointestinal pain were the
most common adverse events, being experienced by 13
(20.3%) and 10 (15.6%) patients, respectively. Other
common adverse events were fatigue (8 patients, 12.5%),
headache (8 patients, 12.5%), hyperhidrosis (8 patients,
12.5%), vomiting (7 patients, 10.9%), and dyspepsia (7
patients, 10.9%). During the 4-month follow-up period,
16 patients (26.6%) out of the 60 patients who started the
follow-up period with Suboxone reported an adverse
event (Table 4). One patient discontinued treatment with
Suboxone during the 4-week study period due to adverse
events, and 5 patients discontinued due to adverse events
during the follow-up period. There were no deaths or
other serious adverse events reported for patients in the
study. There was no apparent relationship between the
average Suboxone daily dose taken during the 4-week
study period and the reporting of adverse events.
Discussion
The study has several limitations. Due to the retrospective
nature of the study, there were no control groups and the
results are only descriptive. However, the patient data
were used to assess any general trends associated with the
Table 2: Induction and transfer dose (n = 64)
n (%)
Switched to same dose of Suboxone as Subutex 58 (90.6)
Switched to higher dose of Suboxone than Subutex 1 (1.6)
Switched to lower dose of Suboxone than Subutex 2 (3.1)
Titrated with Subutex during switch 3 (4.7)
a59 patients reported history of heroin use
Table 3: Maintenance dose weeks 1–4 (n = 64)
n (%)
Treated with Suboxone only throughout 4-week study period 53 (82.8)
Stayed at same dose of Suboxone only throughout 4-week study period 46 (71.9)
Dose reduction 4 (6.3)
Dose increase 1 (1.1)
Temporary dose change 2 (3.1)
Titrated1 with Subutex throughout 4-week study period 7 (11)
Discontinued treatment with Suboxone during 4-week study period 4 (6.2)
1patients had at the same time Suboxone and Subutex, first day 50:50 and during the first week gradually to Suboxone onlySubstance Abuse Treatment, Prevention, and Policy 2008, 3:16 http://www.substanceabusepolicy.com/content/3/1/16
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switch to Suboxone, which may provide an insight into
the best clinical practices for using Suboxone as a replace-
ment for Subutex. Also the number of the patents is rela-
tively low but represents more than 30% of all
buprenorphine treated patients in Finland at the study
time and nearly all of the patients at the 5 centers. A sur-
vival analysis of the client characteristics and history
regarding the time to drop out could have been interest-
ing. Given the relatively small sample size and the scope
of this study, however, this sample may not have suffi-
cient power to detect any but the strongest patterns. Satis-
faction and compliance differed significantly amongst the
treatment centers, thus site specific issues might account
for findings also.
The main aim of this study was to follow the medication
dose and adverse events during a transfer from buprenor-
phine to buprenorphine-naloxone combination. The pos-
sible dose adjustments were decided by the doctors and
were based on each individual's weaning, withdrawal
symptoms and adverse events.
During the first four weeks, 50% of the patients reported
adverse events. However, only one patient discontinued
Suboxone due to adverse events or dissatisfaction, and
one patient left the treatment program (retention rate of
98.5%). This indicates that the side effects at this point
probably might not predict patients' likelihood of staying
in treatment. Indeed, patient records indicate that many
of the reported adverse events were interpreted as being
the result of anxiety about being forced to switch to Sub-
oxone. However, it is notable that during 4 month follow
up period only 43.3% of the patients continued with Sub-
oxone and 16 (61.5%) of these 26 patients also reported
adverse events. It should be noted anxiety interpretation is
more of a speculation than measured assessment.
Interestingly, over half of the patients still on Suboxone
during the 4 month follow up asked for a dose reduction
of Suboxone. This may indicate that the adverse events
could be related to higher buprenorphine serum levels,
because buprenorphine in Suboxone has slightly higher
sublingual bioavailability than the buprenorphine in Sub-
utex [6]. The dose reductions of Suboxone were mainly
done during the follow-up period which may indicate that
bioavailability of high dose of Suboxone in the long term
should be more thoroughly investigated. It should be
noted, however, that the earlier Australian study [5] had
found a need for a dose increase, rather than a decrease,
when switching from buprenorphine to the combination
medication, that could be related to the "low" (12 mg)
average dose of Suboxone in that study.
During the follow-up period relative high number of
patients (56.7%) discontinued with Suboxone. Most of
them were either transferred to methadone (21.7%), back
to Subutex (15%), discontinued (11.7%) the treatment or
moved to other treatment centers (8.3%, no records). The
most common reason for methadone transfer generally in
Finland is polydrug abuse. However, in this study misuse
of buprenorphine and/or lack of compliance accounted
almost half of the discontinuations during the follow-up
period. It is possible that psychiatric distress, when
patients did not feel confident with the forced transfer
from Subutex to Suboxone, may lead to "illegally top-up"
with Subutex, that in turn could lead to medication
Table 4: Summary of adverse events by type and study period.
SOC Preferred Term Adverse Events 4-Weeks (n) (%)a Adverse Events Follow up (n) (%)b
Patients 64 60
Patients who Experienced Adverse Events 32 50.0 16 26.6
Palpitations 4 6.3 0 0
Abdominal Pain Upper 3 4.7 3 4.9
Diarrhea 4 6.3 2 3.3
Dyspepsia 7 10.9 0 0
Gastrointestinal Pain 10 15.6 3 4.9
Nausea 13 20.3 8 13.1
Vomiting 7 10.9 2 3.3
Asthenia 2 3.1 2 3.3
Fatigue 8 12.5 9 14.8
Pain 4 6.3 0 0
Headache 8 12.5 6 9.8
Tremor 4 6.3 1 1.6
Insomnia 4 6.3 2 3.3
Irritability 1 1.6 3 4.9
Hyperhidrosis 8 12.5 3 4.9
Rash 2 3.1 2 3.3
a: Percentage based on all 64 patients. b: Percentage based on the 60 patients who were treated with Suboxone during the follow-up period.Publish with BioMed Central    and   every 
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change to methadone. It is possible also, that because the
high illicit use of buprenorphine in Finland [5], the treat-
ing personnel had a mistrust on patients reports of Subox-
one adverse events, and instead of chancing back to
Subutex patients were changed to methadone. Thus, the
"forced" transfer event could be a unique situation in Fin-
land and may not be present elsewhere i.e. in USA and
Canada, where Suboxone is the main medication.
Switching from Subutex to Suboxone did not increase
abuse of other opioids. Based on the retrospective nature
and small numbers in the study, no solid conclusions
about Suboxone diversion can be done. However, inter-
estingly during the follow-up period of the 60 opioid
dependent patients, only 5 patients attempted to misuse
Suboxone. Furthermore, they reported that while they
tried to inject Suboxone, they would not repeat the expe-
rience, suggesting that the transfer to Suboxone may also
serve as part of an overall strategy to curb misuse of
buprenorphine.
In conclusion, a transfer from Subutex to Suboxone
should be carefully discussed and planned in advance
with the patients and after the transfer adverse events
should be regularly monitored. With regard to buprenor-
phine abuse, the combination product seems to have a
more favorable safety profile than treatment with
buprenorphine alone. The results of this study suggest
that in high dose Suboxone treatment, dose adjustments
should be considered, especially in the later phase of the
treatment, if patients report an unusually high number of
adverse events. Also based on the clinical data gathered it
is recommended that transfers should be discussed and
planned in advance with the patients to minimize psychi-
atric distress and lack of compliance leading to lower
retention rates.
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